Table 1.
CLPTM1L protein levels are enhanced in pancreatic cancer
|
|
|
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Score
|
Mayo Clinic TMAs
|
SEER TMA
|
|||||||||||||||
| Group | Value | Normal TMA1 | PanIN TMA1 | PDAC TMA1 | PDAC GEM | Islet Cell TMA | Normal | PDAC | Islet Cell | ||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
|
|
|
|
|
|
|
|
|
||||||||||
| Negative | 0–1 | 2 | 66.7 | 6 | 46.2 | 25 | 22.5 | 10 | 6.4 | 0 | 0.0 | 8 | 57.1 | 59 | 53.2 | 3 | 42.9 |
| Weak | 2–4 | 1 | 33.3 | 6 | 46.2 | 42 | 37.8 | 20 | 12.8 | 0 | 0.0 | 6 | 42.9 | 47 | 42.3 | 1 | 14.3 |
| Intermediate | 5–8 | 0 | 0 | 1 | 7.7 | 31 | 27.9 | 49 | 31.4 | 2 | 4.9 | 0 | 0 | 4 | 3.6 | 2 | 28.6 |
| Strong | 9–16 | 0 | 0 | 0 | 0.0 | 13 | 11.7 | 77 | 49.4 | 39 | 95.1 | 0 | 0 | 1 | 0.9 | 1 | 14.3 |
|
|
|
|
|
|
|
|
|
||||||||||
| Total | 3 | 100 | 13 | 100 | 111 | 100 | 156 | 100 | 41 | 100 | 14 | 100 | 111 | 100 | 7 | 100 | |
|
|
|
||||||||||||||||
Combined staining intensity and extent for CLPTM1L by immunohistochemistry in normal-derived pancreas, PanIN, PDAC and pancreatic islet cell tumors. CLPTM1L immunohistochemical staining extent (area) and intensity was scored from 0–4 and the combined extent*intensity calculated and shown above (histoscore). Acronyms are as follows for the Mayo Clinic and SEER TMAs used: PanIN: pancreatic intraepithelial neoplasia; PDAC: pancreatic ductal adenocarcinoma, Islet cell: Islet cell tumors, GEM: gemcitabine.